Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease

Human Gene Therapy

Volumn 11, Issue 1, 2000, Pages 179-190

  Déglon, Nicole ^a   Tseng, Jack L ^a   Bensadoun, Jean Charles ^a   Zurn, Anne D ^a   Arsenijevic, Yvan ^a   De Almeida, Luis Pereira ^a   Zufferey, Romain ^b   Trono, Didier ^b   Aebischer, Patrick ^a,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; LENTIVIRINAE; NONHUMAN; PARKINSON DISEASE; RAT;

ANIMALS; CELL LINE; DNA, COMPLEMENTARY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; LENTIVIRUS; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PROSENCEPHALON; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 0033977265     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050016256     Document Type: Article

References (53)

1. Beck, K.D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R.A., Rosenthal, A., and Hefti, F. (1995). Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature (London) 373, 339-341.
2. Bilang-Bleuel, A., Revah, F., Colin, P., Locquet, I., Robert, J.-J., Mallet, J., and Horellou, P. (1997). Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 94, 8818-8823.
3. Blömer, U., Naldini, L., Kafri, T., Trono, D., Verma, I.M., and Gage, F.H. (1997). Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71, 6641-6649.
4. Bohn, M.C., Choi-Lundberg, D.L., Davidson, B.L., Leranth, C., Kozlowski, D.A., Smith, J.C., O'Banion, M.K., and Redmond, D.E. (1999). Adenovirus-mediated transgene expression in nonhuman primate brain. Hum. Gene Ther. 10, 1175-1184.
5. Choi-Lundberg, D.L., Lin Q., Chang, Y.-N., Chiang, Y.L., Hay, C.M., Mohajeri, H., Davidson, B.L., and Bohn, M.C. (1997). Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275, 838-841.
6. Donello, J.E., Beeche, A.A., Smith, G.J., III, Lucero, G.R., and Hope, T.J. (1996). The hepatitis B virus posttranscriptional regulatory element is composed of two subelements. J. Virol. 70, 4345-4351.
7. Donello, J.E., Loeb, J.E., and Hope, T.J. (1998). Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J. Virol. 72, 5085-5092.
8. Dull, T., Zufferey, R., Kelly, M., Mandel, R.J., Nguyen, M., Trono, D., and Naldini, L. (1998). A third generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471.
9. Gallichan, W.S., Kafri, T., Krahl, T., Verma, I.M., and Sarvetnick, N. (1998). Lentivirus-mediated transduction of islet grafts with interleukin-4 results in sustained gene expression and protection from insulitis. Hum. Gene Ther. 9, 2717-2726.
10. Gash, D.M., Zhang, Z., Ovadia, A., Cass, W.A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P.A., Collins, F., Hoffer, B.J., and Gerhardt, G.A. (1996). Functional recovery in parkinsonian monkeys treated with GDNF. Nature (London) 380, 252-255.
11. Gasmi, M., Glynn, J., Jin, M.-J., Jolly, D.J., Yee, J.-K., and Chen, S.-T. (1999). Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J. Virol. 73, 1828-1834.
12. Gasser, T. (1998). Genetics of Parkinson's disease. Ann. Neurol. 44, S53-S57.
13. Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U.S.A. 89, 5547-5551.
14. Hagg, T., and Varon, S. (1993). Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc. Natl. Acad. Sci. U.S.A. 90, 6315-6319.
15. Hauser, R.A., Freeman, T.B., Snow, B.J., Nauert, M., Gauger, L., Kordower, J.H., and Olanow, C.W. (1999). Long-term evaluation of bilateral fetal nigral transplantation in Parkinson's disease. Arch. Neurol. 56, 179-187.
16. Henderson, C.E., Phillips, H.S., Pollock, R.A., Davies, A.M., Lemeulle, C., Armanini, M., Simpson, L.C., Moffet, B., Vandlen, R.A., Koliatsos, V.E., and Rosenthal, A. (1995). GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266, 1062-1064.
17. Horellou, P., and Mallet, J. (1997). Gene therapy for Parkinson's disease. Mol. Neurobiol. 15, 241-256.
18. Hou, J.G., Lin, L.-F.H., and Mytilineou, C. (1996). Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survial and regrowth after damage by 1-methyl-4-phenylpyridinum. J. Neurochem. 66, 74-82.
19. Ju, Q., Edelstein, D., Brendel, M.D., Brandhorst, D., Brandhorst, H., Bretzel, R.G., and Brownlee, M. (1998). Transduction of non-dividing adult human pancreatic beta cells by an integrating lentivital vector. Diabetologia 41, 736-739.
20. Kafri, T., Blömer, U., Peterson, D.A., Gage, F.H., and Verma, I.M. (1997). Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nature Genet. 17, 314-317.
21. Kearns, C.M., and Gash, D.M. (1995). GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 672, 104-111.
22. Kim, V.N., Mitrophanous, K., Kingsman, S.M., and Kingsman, A.J. (1998). Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol. 72, 811-816.
23. Knüsel, B., Beck, K.D., Winslow, J.W., Rosenthal, A., Burton, L.E., Widmar, H.R., Nikolics, K., and Hefti, F. (1992). Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. J. Neurosci. 12, 4391-4402.
24. Kordower, J.H., Bloch, J., Ma, S., CHU, Y., Palfi, S., Roitberg, B., Emborg, M., Hantraye, P., Déglon, N. and Aebischer, P. (1999). Lentiviral gene transfer to the nonhuman primate brain. Exp. Neurol. 160, 1-16.
25. Krack, P., Benazzouz, A., Pollak, P., Limousin, P., Piallat, B., Hoffmann, D., Xie, J., and Benabid, A.L. (1998). Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Mov. Disord. 13, 907-914.
26. Lin, L.-F.H., Doherty, D.H., Lile, J.D., Bektesh, S., and Collins, F. (1993). GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130-1132.
27. Mandel, R.J., Spratt, S.K., Snyder, R.O., and Leff, S.E. (1997). Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. U.S.A. 94, 14083-14088.
28. Miyoshi, H., Takahashi, M., Gage, F.H., and Verma, I.M. (1997). Stable and efficient gene transfer into the retina using a HIV-based lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 94, 10319-10323.
29. Miyoshi, H., Blömer, U., Takahashi, M., Gage, F.H., and Verma, I.M. (1998). Development of a self-inactivating lentivirus vector. J. Virol. 72, 8150-8157.
30. Naldini, L. (1998). Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr. Opin. Biotechnol. 9, 457-463.
31. Naldini, L., Blömer, U., Gage, F.H., Trono, D., and Verma, I.M. (1996a). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 93, 11382-11388.
32. Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M., and Trono, D. (1996b). In vivo gene delivery and stable transduction of nondividing cells by a lenti viral vector. Science 272, 263-267.
33. Olanow, C.W., Kordower, J.H., and Freeman, T.B. (1996). Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurol. Sci. 19, 102-109.
34. Paxinos, G., and Watson, C. (1998). The Rat Brain in Stereotaxic Coordinates. (Academic Press, London).
35. Rebolledo, M.A., Krogstad, P., Chen, F., Shannon, K.M., and Klitzner, T.S. (1998). Infection of human fetal cardiac myocytes by a human immunodeficiency virus-1-derived vector. Circ. Res. 83, 738-742.
36. Régulier, E., Schneider, B., Déglon, N., Beuzard, Y., and Aebischer, P. (1998). Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther. 5, 1014-1022.
37. Rosenblad, C., Martinez-Serrano, A., and Björklund, A. (1996). Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 75, 979-985.
38. Sauer, H., Rosenblad, C., and Björklund, A. (1995). Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. U.S.A. 92, 8935-8939.
39. Sautter, J., Tseng, J.L., Braguglia, D., Aebischer, P., Spencer, C., Seiler, R.W., Widmer, H.R., and Zurn, A.D. (1998). Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp. Neurol. 149, 230-236.
40. Schierle, G.S., Hansson, O., Leist, M., Nicotera, P., Widner, H., and Brundin, P. (1999). Caspase inhibition reduces apoptosis and increases survival or nigral transplants. Nature Med. 5, 97-100.
41. Sutton, R.E., Wu, H.T.M., Rigg, R., Böhnlein, E., and Brown, P.O. (1998). Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells. J. Virol. 72, 5781-5788.
42. Tomac, A., Lindqvist, E., Lin, L.-F.H., Gren, S.O., Young, D., Hoffer, B.J., and Olson, L. (1995). Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature (London) 373, 335-339.
43. Trupp, M., Rydén, M., Jörnvall, H., Funakoshi, H., Timmusk, T., Arenas, E., and Ibáñez, C.F. (1995). Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J. Cell Biol. 130, 137-148.
44. Tseng, J.L., Baetge, E.E., Zurn, A.D., and Aebischer, P. (1997). GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci. 17, 325-333.
45. Tseng, J.L., Bruhn, S.L., Zurn, A.D., and Aebischer, P. (1998). Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy. NeuroReport 9, 1817-1822.
46. Wang, Y., Tien, L.T., Lapchak, P.A., and Hoffer, B.J. (1996). GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats. Cell Tissue Res. 286, 225-233.
47. Yan, Q., Matheson, C., and Lopez, O.T. (1995). In vivo neurotrophic effects of GDNF in neonatal and adult facial motor neurons. Nature (London) 373, 341-344.
48. Yurek, D.M. (1998). Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp. Neurol. 153, 195-202.
49. Zufferey, R., Nagy, D., Mandel, R.J., Naldini, L., and Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnol. 15, 871-875.
50. Zufferey, R., Dull, T., Mandel, R.J., Bukovsky, A., Quiroz, D., Naldini, L., and Trono, D. (1998). Self-inactivating lentiviral vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880.
51. Zufferey, R., Donello, J.E., Trono, D., and Hope, T.J. (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73, 2886-2892.
52. Zurn, A.D., and Werren, F. (1994). Development of CNS cholinergic neurons in vitro: Selective effects of CNTF and LIF on neurons from mesencephalic cranial motor nuclei. Dev. Biol. 163, 309-315.
53. Zurn, A.D., Baetge, E.E., Hammang, J.P., Tan, S.A. and Aebischer, P. (1994). Glial cell line-derived neurotrophic factor (GDNF), a new neurotrophic for motoneurons. NeuroReport 6, 113-118.